This article is precisely the kind of early signal we've been waiting for — direct testimony from a carer in the Phase 2b trial of Xanamem showing real-world cognitive improvement. As Dr. Gourlay reminds us, Xanamem is first-in-class, targets cortisol, and is designed to treat the underlying biology of Alzheimer's, not just reduce plaques.
This isn't retail hype. It's not message board speculation. This is a national newspaper article, quoting Actinogen's CEO and a real family seeing results.We're not just talking potential anymore. We're starting to see it in action.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.54M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 1.9¢ | $128.6K | 6.390M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3337643 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 1075545 | 5 |
View Market Depth
| Last trade - 15.57pm 13/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |